MimiX Biotherapeutics ^Company

MimiX Biotherapeutics is a biotech company that aims to develop biofabrication technology for tissue manufacturing for therapeutic and diagnostic purposes. They use a proprietary technology called Sound Induced Morphogenesis (SIM) to create tissue-relevant architectures using sound waves and cells, stem cells, spheroids, organoids, and bioactives. The company was established in 2019 and has received investment from Heraeus. Their goal is to provide an ultra-fast biomanufacturing technology capable of creating patient-specific biological tissue equivalents for regenerative, personalized, and precision medicine.